– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways – – Data ...
- Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINE TM programs anticipated in 2024 - - WTX-124: updated interim monotherapy dose-escalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results